Results for 'bevacizumab'

7 found
Order:
  1.  59
    Cost‐utility analysis of bevacizumab versus ranibizumab in neovascular age‐related macular degeneration using a Markov model.Jignesh J. Patel, Margaret As Mendes, Mark Bounthavong, Melissa Ld Christopher, Daniel Boggie & Anthony P. Morreale - 2012 - Journal of Evaluation in Clinical Practice 18 (2):247-255.
  2.  26
    Off-label use of bevacizumab in the treatment of retinal disease: ethical implications.Landon James Rohowetz - 2019 - Journal of Medical Ethics 45 (10):668-672.
    Anti-vascular endothelial growth factor therapy has revolutionised the treatment of a variety of ophthalmic conditions and has become the first-line therapy for a range of retinal diseases. Bevacizumab, a VEGF inhibitor first approved for the treatment of colorectal cancer, has been shown to be nearly or virtually as effective and safe as other anti-VEGF therapies in the treatment of certain retinal diseases but is not approved or registered by the Food and Drug Administration or European Medicines Agency. While other (...)
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  3.  62
    Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).Catherine Rhodes, John Harris, John Sulston & Catherine Spanswick - 2012 - Journal of Medical Ethics 38 (3):187-189.
    There are several good reasons for the UK Department of Health to recommend the appraisal of bevacizumab for the treatment of eye conditions by the National Institute for Health and Clinical Excellence. These reasons will extend to other drugs when similar situations arise in the future.
    Direct download (8 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  4.  24
    Dynamic Modeling of the Angiogenic Switch and Its Inhibition by Bevacizumab.Dávid Csercsik & Levente Kovács - 2019 - Complexity 2019:1-18.
    We formulate a dynamic model of vascular tumor growth, in which the interdependence of vascular dynamics with tumor volume is considered. The model describes the angiogenic switch; thus the inhibition of the vascularization process by antiangiogenic drugs may be taken into account explicitly. We validate the model against volume measurement data originating from experiments on mice and analyze the model behavior assuming different inputs corresponding to different therapies. Furthermore, we show that a simple extension of the model is capable of (...)
    No categories
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  5.  26
    Modeling of Tumor Growth Incorporating the Effects of Necrosis and the Effect of Bevacizumab.Dániel András Drexler, Johanna Sápi & Levente Kovács - 2017 - Complexity:1-10.
    No categories
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  6.  83
    Glioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations.Susan V. Ellor, Teri Ann Pagano-Young & Nicholas G. Avgeropoulos - 2014 - Journal of Law, Medicine and Ethics 42 (2):171-182.
    While primary malignant brain tumors account for only two percent of all adult cancers, these neoplasms cause a disproportionate amount of cancer-related disabilities and death. The five-year survival rates for brain tumors are the third lowest among all types of cancer. Malignant gliomas comprise the most common types of primary central nervous system tumors and have a combined incidence of five to eight cases per 100,000 people. The median survival rate of conservatively treated patients with malignant gliomas is 14 weeks; (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  7.  17
    Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer.Ana R. Quesada, Miguel Ángel Medina & Emilio Alba - 2007 - Bioessays 29 (11):1159-1168.
    Angiogenesis plays an essential role in tumor growth, invasion and metastasis. After initial pessimism about the usefulness of the antiangiogenic therapeutic approach for cancer, interest has increased in the development of antiangiogenic compounds after the first clinical approval of an antiangiogenic therapy. The anti‐vascular endothelial growth factor (VEGF) antibody bevacizumab has recently been approved for use in combination with chemotherapy for the treatment of metastatic colorectal and non‐small cell lung cancer patients. However, no survival benefit has been demonstrated in (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark